Who Is Buying Gilead Sciences? Hedge Fund Activity in 2026

Gilead Sciences has quietly become one of the most important biopharmaceutical companies in the world. Best known for its revolutionary hepatitis C cures (Sovaldi, Harvoni) and its HIV franchise (Biktarvy, Descovy), Gilead has more recently expanded into oncology through its acquisition of Immunomedics and the blockbuster cancer drug Trodelvy. The company generates massive free cash flow, pays a solid dividend, and has been one of the steadier performers in the volatile biotech sector.

The latest 13F filings reveal an evenly divided institutional landscape: 6 funds are buying and 6 are selling, with 4 holding steady. This perfect split creates an unusual tension — but the dollar amounts tell a much more nuanced story, with buyers deploying significantly larger capital than sellers.

Gilead Sciences Institutional Snapshot

A 6-to-6 buy-sell ratio looks balanced on the surface, but the scale of buying dwarfs the selling. The top three buyers alone — Vanguard, Fidelity, and State Street — hold a combined $34.5 billion in Gilead stock and all increased their positions. The sellers are trimming relatively smaller allocations. This is a classic case where the headline ratio masks a strongly bullish undercurrent.

Who's Buying Gilead Sciences?

The buyer list reads like a who's who of the largest and most influential institutional investors:

Vanguard Group — $16.9B (Increased) Vanguard's Gilead position is an absolute behemoth at $16.9 billion. This is one of the largest single-stock positions in the entire pharmaceutical sector across all institutional holders. The increase reflects both passive index inflows and Gilead's strong performance, but the magnitude of this holding makes Vanguard a dominant force in GILD's shareholder base.

Fidelity Investments — $9.2B (Increased) Fidelity's active managers have pushed their Gilead allocation to $9.2 billion — a massive increase that signals genuine conviction. Fidelity's healthcare research team is one of the deepest on Wall Street, and their continued buying suggests they see significant upside in Gilead's evolving product portfolio, particularly as Biktarvy's dominance in HIV continues and Trodelvy gains market share in oncology.

State Street — $8.4B (Increased) State Street rounds out the mega-cap institutional trio with $8.4 billion in Gilead stock. The fact that all three of the largest institutional managers are simultaneously increasing positions is a powerful signal — it means broad-based institutional demand is driving capital into GILD from multiple investment frameworks.

T. Rowe Price — $3.2B (Increased) T. Rowe Price's $3.2 billion position represents a significant active management bet on Gilead. As one of the most respected growth-at-a-reasonable-price (GARP) investors, T. Rowe's increased allocation suggests they view Gilead as offering compelling value relative to its growth prospects — particularly in the oncology pipeline.

Baker Bros Advisors — $717.9M (Increased) Baker Brothers, one of the most successful biotech-specialist hedge funds in history, increased its Gilead position to $717.9 million. This is a fund that lives and breathes pharmaceutical pipeline analysis. Their continued buying signals deep confidence in Gilead's clinical programs and commercial execution. When Baker Bros is adding, the biotech community takes notice.

Appaloosa Management — $376.5M (Increased) David Tepper's Appaloosa pushed its Gilead stake to $376.5 million, a substantial position for a fund known for concentrated, high-conviction bets. Tepper typically gravitates toward situations where he sees value that the market is underappreciating, and this increase suggests he believes Gilead's cash generation and pipeline are not fully reflected in the stock price.

Who's Selling Gilead Sciences?

Six funds reduced their exposure, though the aggregate selling is far smaller than the buying:

Canyon Capital — $579.3M (Decreased) Canyon trimmed its position but still holds $579.3 million — a very significant stake. Canyon's approach blends credit and equity analysis, and their reduction may reflect portfolio-level risk management rather than a bearish view on Gilead's fundamentals.

Citadel Advisors — $543.1M (Decreased) Ken Griffin's Citadel reduced to $543.1 million. Citadel's multi-strategy approach means individual position changes are often driven by relative value considerations — they may be rotating into other healthcare names they find more attractive on a near-term basis while maintaining substantial Gilead exposure.

Renaissance Technologies — $389.6M (Decreased) The quant giant reduced to $389.6 million. Renaissance's algorithmic models are extremely sensitive to price momentum and statistical patterns, and this reduction likely reflects model-driven repositioning rather than a fundamental assessment of Gilead's business quality.

Bridgewater Associates — $40.9M (Decreased) Bridgewater's reduction to $40.9 million reflects the macro fund's ongoing adjustment of its healthcare allocation. The position remains small relative to Bridgewater's overall book, suggesting pharmaceutical exposure isn't a core part of their current macro thesis.

D.E. Shaw — $26.9M (Decreased) The quant fund trimmed to $26.9 million, a relatively small position that suggests Gilead is a minor allocation within Shaw's broader portfolio. The reduction is modest and unlikely to signal strong conviction in either direction.

Millennium Management — $19M (Decreased) Millennium's pod-based structure means position changes often reflect individual portfolio manager decisions rather than a firm-wide view. The trim to $19 million is minor in the context of Millennium's overall capital deployment.

Notable Moves

The dominant theme this quarter is the overwhelming scale of buying versus selling. While the fund count is evenly split at 6-6, the dollar amounts tell a completely different story:

• Total buying-side capital: Vanguard ($16.9B) + Fidelity ($9.2B) + State Street ($8.4B) + T. Rowe ($3.2B) + Baker Bros ($717.9M) + Appaloosa ($376.5M) = ~$38.8 billion in bullish positioning
• Total selling-side capital: Canyon ($579.3M) + Citadel ($543.1M) + Renaissance ($389.6M) + remaining sellers (~$86.8M) = ~$1.6 billion in reduced positioning

The buying-side capital outweighs selling by roughly 24-to-1. This is one of the most lopsided dollar-weighted signals in our entire coverage universe.

Baker Bros' continued accumulation at $717.9 million deserves special attention. As perhaps the most successful biotech-focused fund in history, their positioning often foreshadows multi-year moves in pharmaceutical stocks. Their conviction in Gilead alongside T. Rowe Price's $3.2 billion position creates a powerful fundamental-investor consensus.

What This Signals

The institutional picture for Gilead Sciences is far more bullish than the 6-6 headline ratio suggests. Here's the nuanced reading:

Mega-cap institutions are all-in. When Vanguard, Fidelity, and State Street are all increasing simultaneously — representing a combined $34.5 billion — it creates a structural demand floor for the stock. These positions are sticky and unlikely to reverse quickly.

Biotech specialists are adding. Baker Bros' increase to $717.9 million is arguably the most informative signal in this entire analysis. This fund has the deepest biotech expertise in the hedge fund world, and their continued buying suggests Gilead's pipeline has underappreciated optionality.

The HIV franchise provides a fortress. Biktarvy's dominance in HIV treatment gives Gilead a predictable cash flow base that institutional investors love. This allows the company to fund its oncology expansion (Trodelvy, cell therapies) without balance sheet risk — a combination that appeals to both value and growth investors.

Selling is tactical, not structural. None of the six sellers exited their positions entirely. They're trimming around the edges, likely for portfolio management reasons. The average selling-side position is still in the hundreds of millions — these funds remain meaningfully invested in GILD.

Dividend appeal supports the floor. Gilead's dividend yield makes it attractive to income-oriented institutional mandates, creating natural demand from pension funds, endowments, and income-focused mutual funds. This structural demand helps explain why even selling is modest.

For individual investors, the message is clear: institutional money is flowing strongly into Gilead Sciences, with the dollar-weighted signal overwhelmingly bullish despite an even fund count. The combination of Baker Bros' biotech expertise, T. Rowe's GARP discipline, and mega-cap index support creates a strong institutional foundation for the stock.

---

Track GILD institutional activity and portfolio changes in real time at app.freenance.io/smart-money/ticker/GILD.

Related Articles

• Who Is Buying Moderna? Hedge Fund Activity in 2026
• Who Is Buying Regeneron? Hedge Fund Activity in 2026
• Who Is Buying Vertex Pharmaceuticals? Hedge Fund Activity in 2026

FAQ

Which hedge funds are buying Gilead Sciences right now?

13F filings show six tracked funds increased their GILD positions, including Vanguard ($16.9B), Fidelity ($9.2B), State Street ($8.4B), T. Rowe Price ($3.2B), Baker Bros Advisors and Appaloosa. The buying-side capital outweighs the selling-side by roughly 24-to-1 on a dollar-weighted basis.

Why is Gilead's HIV franchise important to institutional investors?

Biktarvy and Descovy generate predictable, high-margin cash flows that anchor Gilead's balance sheet and dividend. 13F commentary across active managers often cites the HIV franchise as the "fortress" that funds the oncology and cell-therapy expansion, which is why many institutions are comfortable holding the stock through cycles.

How does oncology fit into the institutional thesis on GILD?

Through the Immunomedics acquisition and Trodelvy, Gilead has built a meaningful oncology business that institutional analysts view as a growth optionality on top of stable HIV revenue. Buying from biotech-specialist Baker Bros Advisors is often interpreted as confirmation that the pipeline has more value than the current share price reflects.

What about biosimilar and patent-cliff risk?

Biosimilar pressure on legacy hepatitis C drugs and eventual loss of exclusivity on older HIV products are part of the bear case, and the six selling funds may be expressing that concern. 13F data does not show wholesale exits, however — sellers trimmed positions while remaining meaningfully invested.

Is this analysis a recommendation to act on GILD?

No. 13F snapshots describe what institutions reported owning at the end of the quarter and can lag real-time decisions by weeks. The page is informational and should be combined with personal research, time horizon and risk tolerance before any investment decision.